Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction To Survival Analysis01:18

Introduction To Survival Analysis

467
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
467
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

346
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
346
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

228
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
228
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

376
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
376
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

774
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
774
Actuarial Approach01:20

Actuarial Approach

174
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
174

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping the mRS Into the EQ-5D-5L in Patients With Ischemic Stroke.

Stroke·2026
Same author

A Bayesian Modeling Framework for Health Care Resource Use and Costs in Trial-Based Economic Evaluations.

Medical decision making : an international journal of the Society for Medical Decision Making·2025
Same author

Smart Continence Care for People With Profound Intellectual and Multiple Disabilities Within Dutch Residential Care Facilities: Economic Evaluation Alongside a Cluster Randomized Trial.

Journal of medical Internet research·2025
Same author

Bayesian Cost-Effectiveness Analysis Using Individual-Level Data is Sensitive to the Choice of Uniform Priors on the Standard Deviations for Costs in Log-Normal Models.

PharmacoEconomics·2025
Same author

School-based relationship and sexuality education intervention engaging adolescent boys for the reductions of teenage pregnancy: the JACK cluster RCT.

Public health research (Southampton, England)·2023
Same author

Quality of life and societal costs in patients with dilated cardiomyopathy.

European heart journal. Quality of care & clinical outcomes·2023

Related Experiment Video

Updated: Nov 5, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K

A Bayesian Framework for Patient-Level Partitioned Survival Cost-Utility Analysis.

Andrea Gabrio1

  • 1Department of Statistical Science, University College London, London, UK.

Medical Decision Making : an International Journal of the Society for Medical Decision Making
|May 19, 2021
PubMed
Summary

This study introduces a Bayesian framework to analyze complex health economic data from clinical trials, improving cost-effectiveness assessments for end-of-life treatments like non-small cell lung cancer therapies.

Keywords:
Bayesian statisticsSTANeconomic evaluationshurdle modelsmissing datapartitioned survival cost-utility analysis

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K

Related Experiment Videos

Last Updated: Nov 5, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.5K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K

Area of Science:

  • Health economics
  • Biostatistics
  • Clinical trial analysis

Background:

  • Health economic data from clinical trials are crucial for technology appraisal.
  • Partitioned survival analysis is used for end-of-life treatments, combining quality of life and survival data.
  • Effectiveness and cost data often exhibit complexities like nonnormality, spikes, and missingness.

Purpose of the Study:

  • To propose a general Bayesian framework for analyzing complex trial-based partitioned survival cost-utility data.
  • To provide more adequate evidence for policy makers regarding the cost-effectiveness of treatments.
  • To address complexities in health economic data, ensuring unbiased results.

Main Methods:

  • Development of a general Bayesian framework.
  • Application to a real-world case study using data from a clinical trial.
  • Incorporation of methods to handle nonnormality, spikes, and missingness in data.

Main Results:

  • The proposed Bayesian framework effectively accounts for complexities in cost-utility data.
  • The approach yields more adequate evidence for policy decisions.
  • Demonstrated application in assessing the cost-effectiveness of a new treatment for advanced non-small cell lung cancer.

Conclusions:

  • The Bayesian framework offers a robust method for analyzing complex health economic trial data.
  • This approach enhances the reliability of cost-effectiveness evaluations, particularly for end-of-life treatments.
  • Improved evidence generation supports informed policy-making in healthcare technology appraisal.